1. Significor. [package insert] East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
2. Significor LAR. [package insert] East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2014. Gadelha M, Brue T, Fleseriu M, et al. Proactive Monitoring and Early Intervention in the Management of Pasireotide–Induced Hyperglycemia: Lessons from the Phase III, 24–WeekPAOLA study. In: Poster presented at: Endocrine society annual meeting March 5–8. San Diego, CA; 2015.
3. Hyperglycemia Induced by Pasireotide in Patients with Cushing's Disease or Acromegaly;Silverstein;Pituitary,2016
4. Pasireotide B2305 Study Group:A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease;Colao;N Engl J Med,2012
5. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study;Colao;J Clin Endocrinol Metab,2014